Dutch company NLC Health Ventures has announced that it has secured a total of €58 million in funding, including €14 million from a recent funding round, which will be used to “accelerate NLC’s strategic plans for international expansion”, increasing the number of ventures built and “strengthening support” for its existing portfolio.
On its “mission to solve society’s health challenges by turning inventions into medical solutions”, NLC has secured investors in markets including the US, Europe, the Middle East, and Asia. It is currently fundraising for the second close of the NLC Health Impact Fund, which will be closing in May of 2024, and hopes to be able to provide funding for “80-90 ventures” across med tech, biotech and digital health.
Bert-Arjan Millenaar, CEO of NLC Health Ventures, stated that healthcare systems “are under mounting pressure as a result of escalating healthcare demand, a diminishing workforce, and budget constraints. We believe the problems facing the healthcare sector today can be solved through innovation; however, too few innovations make it into market-ready healthcare solutions.”
To learn more about the NLC Health Impact Fund, please click here.
In related news, Germany’s Robert Koch Institute has shared a number of PhD projects for its doctoral programme on AI in Public Health, including AI-based spatial mapping of microbial pathogens; AI-supported annotation of horizontal gene transfer in monitoring antimicrobial resistance; and ML-assisted rapid detection of pathogens using nanopore sequencing.
Elsewhere, the National Institutes of Health (NIH) have announced the launch of the new Cancer Screening Research Network which will focus on evaluating emerging technologies for cancer screening, and shared plans to launch a pilot study to establish “the feasibility of using multi-cancer detection tests in future randomized controlled trials”.
